Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (<i>nab</i>-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Adkins, Douglas R.; Ley, Jessica; Nussenbaum, Brian; Diaz, John P.; Paniello, Randal C.; Thorstad, Wade L.; Gay, Hiram A.; Subramanian, Janakiraman; Wildes, Tanya M.; Mathai, Jessy Mangalathu; Rachocki, T.; Kuperman, D. I.

doi:10.1200/jco.2011.29.15_suppl.5560

JCO

2011

DOI: 10.1200/jco.2011.29.15_suppl.5560

|View full text |Cite

Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Douglas R. Adkins¹,

Jessica Ley²,

Brian Nussenbaum³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2015

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 8 patients experienced grade 3-4 adverse events: infusion reaction to cetuximab (1), neutropenia/pneumonia (1), calf deep vein thrombosis (1), mucositis (1), rectal abscess (1), and asymptomatic neutropenia(3). In general, the regimen had an acceptable toxicity profile[48,49].A retrospective study analyzed the efficacy and tolerability in 23 patients who received cetuximab, docetaxel, cisplatin and 5-fluorouracil as induction chemotherapy for LA-SCCHN[50]. The course of therapy included cetuximab 400 mg/…”

mentioning

confidence: 99%

Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck

Santos

2012

jcru

View full text Add to dashboard Cite

Many advances in the treatment of squamous cell carcinoma of the head and neck have occurred in the past few years. Since the advent of cetuximab, a chimeric monoclonal antibody against epidermal growth factor receptor, the search for other efficacious targeted therapies has awakened the interest and curiosity of researchers and clinicians. Initially, cetuximab demonstrated effectiveness as single agent in heavily pretreated patients diagnosed with head and neck cancer, and has demonstrated to improve locoregional control and survival when combined with radiotherapy. The success of cetuximab has transitioned to other settings and with different modalities such as in combination with other conventional cytotoxic agents in the metastatic setting, combined with radiation therapy as part of concurrent treatment, and lately, in combination with other agents in the induction phase of the sequential approach. In this review, we discuss all different modalities in combination with cetuximab and how cetuximab has been incorporated into other clinical settings with only one goal in mind: improve the survival rates of our patients.

show abstract

mentioning

confidence: 99%

Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck

Santos

2012

jcru

View full text Add to dashboard Cite

show abstract

Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren

Gliese

Busch

Knecht

2014

HNO

View full text Add to dashboard Cite

The two available options for primary radiochemotherapy (RCT) of locally advanced head and neck squamous cell carcinoma are discussed in the current study: concomitant and sequential RCT. At the annual meeting of the American Society of Clinical Oncology (ASCO) 2014, results of current trials on the primary nonsurgical therapy of locally advanced head and neck tumors were presented. A selection of the most important trials will be summarized in this article. Studies including cisplatin-based RCT as standard therapy for locally advanced head and neck tumors, alternatives for cisplatin, combination with targeted therapy, application of the epidermal growth factor receptor (EGFR) antibody cetuximab and the comparison of concomitant and sequential RCT are discussed. The first completely recruited phase III trial comparing concomitant and sequential RCT will also be presented.

show abstract

Erratum zu: Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren

Gliese¹,

Busch²,

Knecht

2015

HNO

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cited by 6 publications

References 0 publications

Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck

Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck

Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren

Erratum zu: Die wichtigsten Studienergebnisse in der Primärtherapie von Kopf-Hals-Tumoren

Contact Info

Product

Resources

About